Brand Name | Status | Last Update |
---|---|---|
mirtazapine | ANDA | 2025-05-28 |
remeron | New Drug Application | 2012-02-17 |
remeron remeronsoltab | New Drug Application | 2025-02-24 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Treatment-resistant depressive disorder | D061218 | — | — | — | — | 1 | — | — | 1 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Esmirtazapine |
INN | esmirtazapine |
Description | Esmirtazapine (ORG-50,081) is a tetracyclic antidepressant drug that was under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors.
|
Classification | Small molecule |
Drug class | tricyclic compounds |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1 |
PDB | — |
CAS-ID | 61337-87-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1366933 |
ChEBI ID | — |
PubChem CID | 3085218 |
DrugBank | DB06678 |
UNII ID | 4685R51V7M (ChemIDplus, GSRS) |